Brain-Computer Interface Registry to Educate Medical Community on BCI Benefits

Synchron has launched a community-centered brain-computer interface (BCI) registry to help patients, carers and clinicians to better understand BCI’s benefits to people with limited mobility.
 
Synchron’s BCI technology is designed to decipher the brain’s neural code and find new ways to restore motor intent to control digital devices. The Synchron BCI represents a novel approach to restoring functionality in patients with limited mobility. The device is non-invasively implanted in the brain by leveraging blood vessels.
 
“We are thrilled to launch our community-centered BCI registry,” Synchron Founder/CEO Tom Oxley said. “There is a grassroots movement happening with BCI. We are creating an avenue for potential users and their physicians to engage and stay connected while we prepare for the next stage of clinical trials.”
 
The Synchron BCI is implanted in the blood vessel on the surface of the brain’s motor cortex via the jugular vein, in a minimally-invasive endovascular procedure. Once implanted, it is designed to detect and wirelessly transmit motor intent from the brain in an effort to enable severely paralyzed patients to control personal devices with hands-free point-and-click.

“BCI technology enables individuals with motor impairment to regain independence,” stated David Lacomis, M.D., principal investigator, chief of the Neuromuscular Division at UPMC, and professor of Neurology and Pathology at the University of Pittsburgh. “By controlling digital devices through one’s own thoughts, BCI offers a transformative path towards performing daily tasks with greater ease and efficiency. From communication to accessing essential services online, BCI technology represents a groundbreaking frontier for individuals and their families.”
 
Synchron is a New York, N.Y.-based neurotechnology company developing an endovascular brain-computer interface (BCI) that aims to restore functionality in patients with severe paralysis. The clinical-stage company is developing a neuroprosthesis to restore motor signaling to control digital devices and autonomy for individuals with motor impairment.